Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease

Journal of Neurology

Volumn 253, Issue 3, 2006, Pages 340-348

  Kaasinen, V ^a   Maguire, R P ^b   Hundemer, H P ^c   Leenders, K L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

FDG; FDOPA; Parkinson's disease; PCA; PET

Indexed keywords

6 FLUORODOPA F 18; FLUORODEOXYGLUCOSE F 18; TRACER;

ADULT; ARTICLE; BIOACCUMULATION; BRAIN FUNCTION; BRAIN METABOLISM; CEREBELLUM; CLINICAL TRIAL; CORPUS STRIATUM; COVARIANCE; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; FEMALE; HEMISPHERIC DOMINANCE; HUMAN; MALE; MONOAMINERGIC SYSTEM; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SEX DIFFERENCE; THALAMUS;

AGED; CEREBRAL CORTEX; CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; DIHYDROXYPHENYLALANINE; FEMALE; FLUORODEOXYGLUCOSE F18; FUNCTIONAL LATERALITY; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; SEX FACTORS;

EID: 33644941246     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-0993-7     Document Type: Article

References (33)

1. Antonini A, Vontobel P, Psylla M, Günther I, Maguire RP, Missimer J, Leenders KL (1995) Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 52:1183-1190
2. Ashburner J, Friston KJ (1999) Nonlinear spatial normalisation using basis functions. Hum Brain Map 7:254-266
3. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, Marsden CD, Frackowiak RS (1990) The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 113:1539-1552
4. 18F]6-fluoro-L-3.4-dihydroxyphenylalanine in the hooded rat. J Neurochem 48:601-608
5. Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, Belakhlef A, Margouleff C, Eidelberg D (2002) Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med 43:1324-1330
6. 18F]fluorodopa positron emission tomographic studies. Mov Disord 5:203-213
7. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S, Fahn S (1994) The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 14:783-800
8. Fahn S, Elton RL, the UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease. Florham Park, NJ: MacMillan Healthcare Information, pp 153-163
9. 18F]fluoro-L-3.4-dihydroxyphenylalanine in the primate. J Neurochem 48:1077-1082
10. Friston K, Holmes AP, Worsley KJ, Poline J-B, Frith CD, Frackowiak R (1995) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Map 2:189-210
11. Garnett ES, Nahmias C, Firnau G (1984) Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci 11:174-179
12. Ghaemi M, Raethjen J, Hilker R, Rudolf J, Sobesky J, Deuschl G, Heiss WD (2002) Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study. Mov Disord 17:782-788
13. 18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab 13:57-69
14. Hu MT, Chaudhuri KR, Jarosz J, Yaguez L, Brooks DJ (2002) An imaging study of parkinsonism among African-Caribbean and Indian London communities. Mov Disord 17:1321-1328
15. Johnson RA, Wichern DW (1998) Applied multivariate statistical analysis. Upper Saddle River: Prentice Hall
16. 2-like receptors in the human brain. Am J Psychiatry 158:308-311
17. 18F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 124:1125-1130
18. Laakso A, Vilkman H, Bergman J, Haaparanta M, Solin O, Syvälahti E, Salokangas RK, Hietala J (2002) Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol Psychiatry 52:759-763
19. 123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 27:867-869
20. Moeller JR, Nakamura T, Mentis MJ, Dhawan V, Spetsieris P, Antonini A, Missimer J, Leenders KL, Eidelberg D (1999) Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 40:1264-1269
21. Moeller JR, Strother SC (1991) A regional covariance approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metab 11: A121-A135
22. Moeller JR, Strother SC, Sidtis JJ, Rottenberg DA (1987) Scaled subprofile model: a statistical approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metab 7:649-658
23. Mozley LH, Gur RC, Mozley PD, Gur RE (2001) Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 158:1492-1499
24. Oertel WH, Schwarz J, Leenders KL, Hundemer HP, Lledo A, Wolters EC on behalf of the Pelmopet-Study Group (2001) Results of a 3 year randomized, double-blind, PET-controlled study of Pergolide vs. L-dopa as Monotherapy in Early Parkinson's Disease (PELMOPET-trial). J Neurol Sci 187(Suppl 1):S444
25. 18F-FDG. Ann Nucl Med 11:251-257
26. Pohjalainen T, Rinne JO, Någren K, Syvälahti E, Hietala J (1998) Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry 155:768-773
27. 18F]dopa-PET study. Brain 122:1637-1650
28. 18F]fluorodeoxyglucose positron emission tomographic region-of-interest data. J Cereb Blood Flow Metab 11:A83-A88
29. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS (1990) Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 28:799-804
30. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34:324-330
31. 123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 41:275-284
32. Vollenweider FX, Maguire RP, Leenders KL, Mathys K, Angst J (1998) Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Res 83:149-162
33. 18F]fluorodeoxyglucose. Methods 27:218-225